Resumen

HERNANDEZ RODRIGUEZ, José; LICEA PUIG, Manuel Emiliano  y  CASTELO ELIAS-CALLES, Lizet. Drugs for loss of weight and metabolic control in obese persons with type 2 diabetes mellitus. Rev Cubana Endocrinol [online]. 2013, vol.24, n.3, pp.323-331. ISSN 1561-2953.

Introduction: obesity is a growing complex and multifactoral disease that frequently affects people from sexes, age groups and social segments in almost all the countries regardless of their economic development. It brings about substantial costs for the health care system, particularly when it is linked to type 2 diabetes mellitus. In this regard, it is necessary to optimize the medical treatment for these patients. Objectives: to describe the drugs that should be used in persons with type 2 diabetes mellitus, who present with overweight or obesity, in order to keep good metabolic control and encourage loss of weight or at least to avoid weight gain. Development: the association of type 2 diabetes mellitus and excessive weight is well-established. The treatment with hypoglycemic such as sulphonylureas, meglitinides, thiazolidonediones and even insulin, may cause weight gain as a potential secondary effect and therefore, it is necessary to use drugs diminishing the weight gain in these persons. Conclusions: the use of metformine and insulin analogue called detemir in patients with type 2 diabetes mellitus and body overweight is associated to neutral effect or to modest loss of body weight. The dipeptidyl peptidase-4, sitagliptin and vildagliptin inhibitors have neutral effect on weight whereas the glucagon-like peptide 1 receptor agonists called exenatide and liraglutide as well as amiline analogue called pramlintide encourage loss of weight.

Palabras clave : type 2 diabetes mellitus; obesity; pharmacotherapy; loss of weight.

        · resumen en Español     · texto en Español     · Español ( pdf )